Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
By SquaredTown on November 28, 2025
FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies Separately, FDA recently issued labeling comments, and labeling discussions have formally begun for the New Drug Application of...